Ignite Creation Date:
2025-12-25 @ 2:06 AM
Ignite Modification Date:
2025-12-26 @ 3:13 AM
Study NCT ID:
NCT05092360
Status:
TERMINATED
Last Update Posted:
2025-08-28
First Post:
2021-10-13
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)
Sponsor:
Mural Oncology, Inc
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-01-10
Start Date Type:
ACTUAL
Primary Completion Date:
2025-01-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-05-08
Completion Date Type:
ACTUAL
First Submit Date:
2021-10-13
First Submit QC Date:
None
Study First Post Date:
2021-10-25
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-06-30
Results First Submit QC Date:
None
Results First Post Date:
2025-08-28
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-08-11
Last Update Post Date:
2025-08-28
Last Update Post Date Type:
ESTIMATED